Teva Pharmaceutical Industries (FRA:TEV) Total Liabilities: €27,514 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
58 GF Score
Price €28.10
GF Value €17.58
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Total Liabilities?

Teva Pharmaceutical Industries FRA:TEV -1.40% 58 Total Liabilities is €27,514 Mil as of Mar. 2026. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.58 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Teva Pharmaceutical Industries's Total Liabilities for the quarter that ended in Mar. 2026 was €27,514 Mil.

Teva Pharmaceutical Industries's quarterly Total Liabilities increased from Sep. 2025 (€27,776.90 Mil) to Dec. 2025 (€28,040.24 Mil) but then declined from Dec. 2025 (€28,040.24 Mil) to Mar. 2026 (€27,513.92 Mil).

Teva Pharmaceutical Industries's annual Total Liabilities declined from Dec. 2023 (€32,418.70 Mil) to Dec. 2024 (€32,093.73 Mil) and declined from Dec. 2024 (€32,093.73 Mil) to Dec. 2025 (€28,040.24 Mil).


Teva Pharmaceutical Industries Total Liabilities Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Total Liabilities Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32,233.47 33,429.87 32,418.70 32,093.73 28,040.24

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29,735.05 28,868.50 27,776.90 28,040.24 27,513.92
FRA:TEV
58GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Teva Pharmaceutical Industries's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11491.424+(13043.996+3252.032
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+252.784+0+0)
=28,040

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=34798.792-6758.556
=28,040

Teva Pharmaceutical Industries's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11705.18+(12365.175+3207.42
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+236.145+0+0)
=27,514

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=34634.6-7120.68
=27,514

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €27,514 Mil mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Total Liabilities of €27,514 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Total Liabilities too high?
Teva Pharmaceutical Industries' current Total Liabilities is €27,514 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Total Liabilities compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Total Liabilities of €27,514 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Total Liabilities is €27,514 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.58, compared to a current price of €28.10 — trading 59.8% above its estimated fair value. The current Total Liabilities is €27,514 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Total Liabilities is €27,514 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €28.10 is trading 59.8% above its estimated GF Value™ of €17.58. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Total Liabilities: €27,514 Mil
  • GF Value™: €17.58 vs. price of €28.10 (59.8% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score

Get the complete analysis for FRA:TEV

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.10
Price
€17.58
GF Value